Resolution of exacerbated rheumatoid arthritis-associated interstitial lung disease under baricitinib treatment

Click to increase image sizeClick to decrease image size

Disclosure statement

TK has received speaking fees and/or honoraria from Tanabe Mitsubishi, Pfizer, Amgen, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Novartis, and Janssen; and grants and speaking fees from GlaxoSmithKline. HT has received speaking fees and/or honoraria from AbbVie, Amgen, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Jansen, Novartis, Sanofi, Tanabe Mitsubishi, and UCB; and research grants from AbbVie, Mochida, and Takeda. HS has received fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Sanofi, AbbVie, GlaxoSmithKline, Gilead, Boehringer Ingelheim, Jansen, Novartis, Chugai, Astellas, Eisai, Asahi Kasei, Taisho Pharmaceutical, AstraZeneca, and Daiichi-Sankyo. KF has received speaking fees and/or honoraria from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Jansen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei, Taisho, and AstraZeneca; and research grants from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Eisai, Tsumura, AbbVie, and Asahi Kasei. The other authors declare no conflicts of interest associated with this manuscript.

Data availability statement

Further anonymized data can be obtained from the corresponding author, [email protected], upon reasonable request.

Consent

Written informed consent for the publication of this report was obtained from the patient.

Ethical approval

Retrospective chart review and publication was approved by the Ethics Committee (11592).